Bioventus Inc
NASDAQ:BVS
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
This alert will be permanently deleted.
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| US |
B
|
Bioventus Inc
NASDAQ:BVS
|
656.3m USD |
Loading...
|
|
| US |
M
|
Medline Inc
NASDAQ:MDLN
|
58.5B USD |
Loading...
|
|
| JP |
|
Hoya Corp
TSE:7741
|
8.8T JPY |
Loading...
|
|
| CH |
|
Alcon AG
SIX:ALC
|
30.8B CHF |
Loading...
|
|
| DK |
|
Coloplast A/S
CSE:COLO B
|
120.8B DKK |
Loading...
|
|
| US |
|
Align Technology Inc
NASDAQ:ALGN
|
11.8B USD |
Loading...
|
|
| UK |
|
ConvaTec Group PLC
LSE:CTEC
|
4.7B GBP |
Loading...
|
|
| CN |
|
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
42.6B CNY |
Loading...
|
|
| CA |
|
Bausch + Lomb Corp
NYSE:BLCO
|
6B USD |
Loading...
|
|
| CH |
|
Ypsomed Holding AG
SIX:YPSN
|
4.2B CHF |
Loading...
|
|
| KR |
H
|
HLB Inc
KOSDAQ:028300
|
7.1T KRW |
Loading...
|
Market Distribution
| Min | -24 813% |
| 30th Percentile | 28.9% |
| Median | 43% |
| 70th Percentile | 60.5% |
| Max | 10 905 714.3% |
Other Profitability Ratios
Bioventus Inc
Glance View
Bioventus, Inc. global medical technology company which focuses on developing and commercializing and proprietary orthobiologic products for the treatment of patients suffering from an array of musculoskeletal conditions. The company is headquartered in Durham, North Carolina and currently employs 1,200 full-time employees. The company went IPO on 2021-02-11. The firm is focused on developing and commercializing clinically and minimally invasive treatments that engage and enhance the body’s natural healing process. The Company’s portfolio of products includes OA joint pain treatment and joint preservation, bone graft substitutes and minimally invasive fracture treatment. The OA joint pain treatment and joint preservation is focused on orthopedics. Its bone graft substitutes (BGSs) offers portfolio of products including human tissue allografts and synthetics. Its BGS products can be used in conjunction with any orthopedic fixation and spinal fusion implant. They are designed to improve bone fusion rates following spinal fusion and other orthopedic surgeries and reduce the need for using the patient’s own bone.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Bioventus Inc is 67.8%, which is above its 3-year median of 65.7%.
Over the last 3 years, Bioventus Inc’s Gross Margin has increased from 66.7% to 67.8%. During this period, it reached a low of 62.9% on Sep 30, 2023 and a high of 67.8% on Sep 27, 2025.
